Lopes, C. D. F., Gonçalves, N. P., Gomes, C. P., Saraiva, M. J., & Pêgo, A. P. (2017). BDNF gene delivery mediated by neuron-targeted nanoparticles is neuroprotective in peripheral nerve injury. Biomaterials, 121, 83 - 96.

Panayiotou, E., Fella, E., Papacharalambous, R., Malas, S., et al. (2017). C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy. PLoS ONE, 12(4).

Sant'Anna, R., Almeida, M. R., Varejao, N., Gallego, P., et al. (2017). Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Scientific Reports, 7.

Gonçalves, N. P., Moreira, J., Martins, D., Vieira, P., et al. (2017). Differential expression of Cathepsin E in transthyretin amyloidosis: From neuropathology to the immune system. Journal of Neuroinflammation, 14(1).

Teixeira, C., Costelha, S., Martins, H. S., Teixeira, A., & Saraiva, M. J. (2017). Doxycycline-tauroursodeoxycholic acid treatment: effects in the heart of a transthyretin V30M transgenic mouse model. Amyloid, 24, 80.

Gonçalves, P., Martins, H., Costelha, S., & Saraiva, M. J. (2017). Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid, 24, 38 - 39.

Pires, R. H., Saraiva, M. J., Damas, A. M., & Kellermayer, M. S. Z. (2017). Force spectroscopy reveals the presence of structurally modified dimers in transthyretin amyloid annular oligomers. Journal of Molecular Recognition, 30(3).

Gonçalves, N. P., Martins, D., & Saraiva, M. J. (2017). The importance of pre-clinical studies in animal models of TTR amyloidosis for the discovery of novel patient disease biomarkers. Amyloid, 24, 83 - 84.

Martins, D., Moreira, J., Gonçalves, N. P., & Saraiva, M. J. (2017). MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy. DMM Disease Models and Mechanisms, 10(10), 1253 - 1260.

Pansieri, J., Plissonneau, M., Stransky-Heilkron, N., Dumoulin, M., et al. (2017). Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting. Nanomedicine, 12(14), 1675 - 1687.

Ferreira, N., Gonçalves, N. P., Saraiva, M. J., & Almeida, M. R. (2016). Curcumin: A multi-Target disease-modifying agent for late-stage transthyretin amyloidosis. Scientific Reports, 6.

Gonçalves, P., Martins, H., Costelha, S., Maia, L. F., & Saraiva, M. J. (2016). Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid, 23(4), 249 - 253.

Vieira, M., Leal, S. S., Gomes, C. M., & Saraiva, M. J. (2016). Evidence for synergistic action of transthyretin and IGF-I over the IGF-I receptor. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1862(4), 797 - 804.

Plissonneau, M., Pansieri, J., Heinrich-Balard, L., Morfin, J. - F., et al. (2016). Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting. Journal of Nanobiotechnology, 14(1).

Teixeira, C. A., Almeida, M. D. R., & Saraiva, M. J. (2016). Impairment of autophagy by TTR V30M aggregates: In vivo reversal by TUDCA and curcumin. Clinical Science, 130(18), 1665 - 1675.

Simões, C. J. V., Almeida, Z. L., Costa, D., Jesus, C. S. H., et al. (2016). A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition. European Journal of Medicinal Chemistry, 121, 823 - 840.

Gonçalves, N. P., Martins, D., & Saraiva, M. J. (2016). Overexpression of Protocadherin-10 in Transthyretin-Related Familial Amyloidotic Polyneuropathy. American Journal of Pathology, 186(7), 1913 - 1924.

Butler, J. S., Chan, A., Costelha, S., Fishman, S., et al. (2016). Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid, 23(2), 109 - 118.

Gonçalves, N. P., Gonçalves, P., Magalhaes, J., Ventosa, M., et al. (2016). Tissue remodeling after interference RNA mediated knockdown of transthyretin in a familial amyloidotic polyneuropathy mouse model. Neurobiology of Aging, 47, 91 - 101.

Alemi, M., Gaiteiro, C., Ribeiro, C. A., Santos, L. M., et al. (2016). Transthyretin participates in beta-amyloid transport from the brain to the liver- involvement of the low-density lipoprotein receptor-related protein 1?. Scientific Reports, 6.

Gomes, J. R., Nogueira, R. S., Vieira, M., Santos, S. D., et al. (2016). Transthyretin provides trophic support via megalin by promoting neurite outgrowth and neuroprotection in cerebral ischemia. Cell Death and Differentiation, 23(11), 1749 - 1764.

Conejos-Sánchez, I., Cardoso, I., Oteo-Vives, M., Romero-Sanz, E., et al. (2015). Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease. Journal of Controlled Release, 198, 80 - 90.

Gonçalves, N. P., Teixeira-Coelho, M., & Saraiva, M. J. (2015). Protective role of anakinra against transthyretin-mediated axonal loss and cell death in a mouse model of familial amyloidotic polyneuropathy. Journal of Neuropathology and Experimental Neurology, 74(3), 203 - 217.

Vieira, M., Gomes, J. R., & Saraiva, M. J. (2015). Transthyretin Induces Insulin-like Growth Factor I Nuclear Translocation Regulating Its Levels in the Hippocampus. Molecular Neurobiology, 51(3), 1468 - 1479.

Gonçalves, N. P., Teixeira-Coelho, M., & Saraiva, M. J. (2014). The inflammatory response to sciatic nerve injury in a familial amyloidotic polyneuropathy mouse model. Experimental Neurology, 257, 76 - 87.

Conejos-Sánchez, I., Cardoso, I., Saraiva, M. J., & Vicent, M. J. (2014). Targeting a rare amyloidotic disease through rationally designed polymer conjugates. Journal of Controlled Release, 178(1), 95 - 100.

Vieira, M., & Saraiva, M. J. (2014). Transthyretin: A multifaceted protein. Biomolecular Concepts, 5(1), 45 - 54.

Ribeiro, C. A., Oliveira, S. M., Guido, L. F., Magalhães, A., et al. (2014). Transthyretin stabilization by iododiflunisal promotes amyloid-? peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model. Journal of Alzheimer's Disease, 39(2), 357 - 370.

Ferreira, N., Santos, S. A. O., Domingues, M. R. M., Saraiva, M. J., & Almeida, M. R. (2013). Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1832(1), 39 - 45.

Misumi, Y., Ando, Y., Gonçalves, N. P., & Saraiva, M. J. (2013). Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis. Laboratory Investigation, 93(8), 911 - 920.

Batista, A. R., Sena-Esteves, M., & Saraiva, M. J. (2013). Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1832(8), 1183 - 1193.

Petrakis, I., Mavroeidi, V., Stylianou, K., Andronikidi, E., et al. (2013). Hsf-1 affects podocyte markers NPHS1, NPHS2 and WT1 in a transgenic mouse model of TTRVal30Met-related amyloidosis. Amyloid, 20(3), 164 - 172.

Petrakis, I., Mavroeidi, V., Stylianou, K., Efthymiou, G., et al. (2013). Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: Does the environment play a role?. Transgenic Research, 22(1), 101 - 116.

Teixeira, A. C., & Saraiva, M. J. (2013). Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: An escape from ERAD. Journal of Cellular and Molecular Medicine, 17(3), 429 - 435.

Vieira, M., & Saraiva, M. J. (2013). Transthyretin regulates hippocampal 14-3-3? protein levels. FEBS Letters, 587(10), 1482 - 1488.

Almeida, M. R., & Saraiva, M. J. (2012). Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin. FEBS Letters, 586(18), 2891 - 2896.

Pires, R. H., Karsai, Á., Saraiva, M. J., Damas, A. M., & Kellermayer, M. S. Z. (2012). Distinct Annular Oligomers Captured along the Assembly and Disassembly Pathways of Transthyretin Amyloid Protofibrils. PLoS ONE, 7(9).

Obici, L., Cortese, A., Lozza, A., Lucchetti, J., et al. (2012). Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study. Amyloid, 19(SUPPL. 1), 34 - 36.

Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2012). Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "In vivo" evidence from FAP mice models. PLoS ONE, 7(1).

Magalhães, J., & Saraiva, M. J. (2012). The heat shock response in FAP: The role of the extracellular chaperone clusterin. Amyloid, 19(SUPPL. 1), 3 - 4.

Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2012). Natural polyphenols as modulators of TTR amyloidogenesis: In vitro and in vivo evidences towards therapy. Amyloid, 19(SUPPL. 1), 39 - 42.

Gonçalves, N. P., Oliveira, H., Pêgo, A. P., & Saraiva, M. J. (2012). A novel nanoparticle delivery system for in vivo targeting of the sciatic nerve: Impact on regeneration. Nanomedicine, 7(8), 1167 - 1180.

Ribeiro, C. A., Saraiva, M. J., & Cardoso, I. (2012). Stability of the Transthyretin Molecule as a Key Factor in the Interaction with A-Beta Peptide - Relevance in Alzheimer's Disease. PLoS ONE, 7(9).

Ribeiro, C. A., Santana, I., Oliveira, C., Baldeiras, I., et al. (2012). Transthyretin decrease in plasma of MCI and AD patients: Investigation of mechanisms for disease modulation. Current Alzheimer Research, 9(8), 881 - 889.

Saraiva, M. J., Magalhaes, J., Ferreira, N., & Almeida, M. R. (2012). Transthyretin deposition in familial amyloidotic polyneuropathy. Current Medicinal Chemistry, 19(15), 2304 - 2311.

Liz, M. A., Leite, S. C., Juliano, L., Saraiva, M. J., et al. (2012). Transthyretin is a metallopeptidase with an inducible active site. Biochemical Journal, 443(3), 769 - 778.

Magalhães, J., & Saraiva, M. J. (2011). Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy. Journal of Neuropathology and Experimental Neurology, 70(12), 1097 - 1106.

Oliveira, S. M., Ribeiro, C. A., Cardoso, I., & Saraiva, M. J. (2011). Gender-dependent transthyretin modulation of brain amyloid-? Levels: Evidence from a mouse model of alzheimer's disease. Journal of Alzheimer's Disease, 27(2), 429 - 439.

Noborna, F., O'Callaghan, P., Hermansson, E., Zhang, X., et al. (2011). Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proceedings of the National Academy of Sciences of the United States of America, 108(14), 5584 - 5589.

Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2011). Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters, 585(15), 2424 - 2430.

Quintela, T., Gonçalves, I., Martinho, A., Alves, C. H., et al. (2011). Progesterone enhances transthyretin expression in the rat choroid plexus in vitro and in vivo via progesterone receptor. Journal of Molecular Neuroscience, 44(3), 152 - 158.

Sárkány, Z., Ikonen, T. P., Ferreira-Da-Silva, F., Saraiva, M. J., et al. (2011). Solution structure of the soluble receptor for advanced glycation end products (sRAGE). Journal of Biological Chemistry, 286(43), 37525 - 37534.

Castro-Rodrigues, A. F., Gales, L., Saraiva, M. J., & Damas, A. M. (2011). Structural insights into a zinc-dependent pathway leading to Leu55Pro transthyretin amyloid fibrils. Acta Crystallographica Section D: Biological Crystallography, 67(12), 1035 - 1044.

Pires, R. H., Saraiva, M. J., Damas, A. M., & Kellermayer, M. S. Z. (2011). Structure and assembly-disassembly properties of wild-type transthyretin amyloid protofibrils observed with atomic force microscopy. Journal of Molecular Recognition, 24(3), 467 - 476.

Niederhauser, J., Lobrinus, J. A., Ochsner, F., Wider, C., et al. (2011). Successful heart and liver transplantation in a swiss patient with glu89lys transthyretin amyloidosis. Transplantation, 91(6), e40 - e42.

Macedo, B., Magalhães, J., Batista, A. R., & Saraiva, M. J. (2010). Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacological Research, 62(6), 514 - 522.

Saraiva, A. M., Cardoso, I., Pereira, M. C., Coelho, M. A. N., et al. (2010). Controlling amyloid-? peptide(1-42) oligomerization and toxicity by fluorinated nanoparticles. ChemBioChem, 11(13), 1905 - 1913.

Santos, S. D., Lambertsen, K. L., Clausen, B. H., Akinc, A., et al. (2010). CSF transthyretin neuroprotection in a mouse model of brain ischemia. Journal of Neurochemistry, 115(6), 1434 - 1444.

Santos, S. D., Fernandes, R., & Saraiva, M. J. (2010). The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiology of Aging, 31(2), 280 - 289.

Martinho, A., Gonçalves, I., Cardoso, I., Almeida, M. R., et al. (2010). Human metallothioneins 2 and 3 differentially affect amyloid-beta binding by transthyretin. FEBS Journal, 277(16), 3427 - 3436.

Saraiva, A. M., Cardoso, I., Saraiva, M. J., Tauer, K., et al. (2010). Randomization of Amyloid-?-Peptide(1-42) Conformation by Sulfonated and Sulfated Nanoparticles Reduces Aggregation and Cytotoxicity. Macromolecular Bioscience, 10(10), 1152 - 1163.

Cardoso, I., Martins, D., Ribeiro, T., Merlini, G., & Saraiva, M. J. (2010). Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: Studies in FAP mouse models. Journal of Translational Medicine, 8.

Magalhães, J., Santos, S. D., & Saraiva, M. J. (2010). ?B-crystallin (HspB5) in familial amyloidotic polyneuropathy. International Journal of Experimental Pathology, 91(6), 515 - 521.

Quintela, T., Gonçalves, I., Baltazar, G., Alves, C. H., et al. (2009). 17?-estradiol induces transthyretin expression in murine choroid plexus via an oestrogen receptor dependent pathway. Cellular and Molecular Neurobiology, 29(4), 475 - 483.

Ferreira, N., Cardoso, I., Domingues, M. R., Vitorino, R., et al. (2009). Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Letters, 583(22), 3569 - 3576.

Rocha, S., Cardoso, I., Börner, H., Pereira, M. C., et al. (2009). Design and biological activity of ?-sheet breaker peptide conjugates. Biochemical and Biophysical Research Communications, 380(2), 397 - 401.

Mairal, T., Nieto, J., Pinto, M., Almeida, M. R., et al. (2009). Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE, 4(1).

Mairal, T., Nieto, J., Pinto, M., Almeida, M. R., et al. (2009). Iodine atoms: A new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE, 4(1).

González, A., Quirante, J., Nieto, J., Almeida, M. R., et al. (2009). Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 19(17), 5270 - 5273.

Fleming, C. E., Mar, F. M., Franquinho, F., Saraiva, M. J., & Sousa, M. M. (2009). Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity. Journal of Neuroscience, 29(10), 3220 - 3232.

Quintela, T., Alves, C. H., Gonçalves, I., Baltazar, G., et al. (2008). 5?-dihydrotestosterone up-regulates transthyretin levels in mice and rat choroid plexus via an androgen receptor independent pathway. Brain Research, 1229, 18 - 26.

Santos, S. D., Magalhães, J., & Saraiva, M. J. (2008). Activation of the heat shock response in familial amyloidotic polyneuropathy. Journal of Neuropathology and Experimental Neurology, 67(5), 449 - 455.

Santos, S. D., Costa, R., Teixeira, P. F., Gottesman, M., et al. (2008). Amyloidogenic properties of transthyretin-like protein (TLP) from Escherichia coli. FEBS Letters, 582(19), 2893 - 2898.

Macedo, B., Batista, A. R., Ferreira, N., Almeida, M. R., & Saraiva, M. J. (2008). Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1782(9), 517 - 522.

Cardoso, I., Brito, M., & Saraiva, M. J. (2008). Extracellular matrix markers for disease progression and follow-up of therapies in familial amyloid polyneuropathy V30M TTR-related. Disease Markers, 25(1), 37 - 47.

Gales, L., Almeida, M. R., Arsequell, G., Valencia, G., et al. (2008). Iodination of salicylic acid improves its binding to transthyretin. Biochimica et Biophysica Acta - Proteins and Proteomics, 1784(3), 512 - 517.

Costa, R., Gonçalves, A., Saraiva, M. J., & Cardoso, I. (2008). Transthyretin binding to A-Beta peptide - Impact on A-Beta fibrillogenesis and toxicity. FEBS Letters, 582(6), 936 - 942.

Sousa, M. M., & Saraiva, M. J. (2008). Transthyretin is not expressed by dorsal root ganglia cells. Experimental Neurology, 214(2), 362 - 365.

Costa, R., Ferreira-Da-Silva, F., Saraiva, M. J., & Cardoso, I. (2008). Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: A mechanism sensitive to the kunitz protease inhibitor. PLoS ONE, 3(8).

Se, H. C., Leight, S. N., Lee, V. M. - Y., Li, T., et al. (2007). Accelerated A? deposition in APPswe/PS1?E9 mice with hemizygous deletions of TTR (transthyretin). Journal of Neuroscience, 27(26), 7006 - 7010.

Liz, M. A., Gomes, C. M., Saraiva, M. J., & Sousa, M. M. (2007). ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. Journal of Lipid Research, 48(11), 2385 - 2395.

Macedo, B., Batista, A. R., Do Amaral, J. B., & Saraiva, M. J. (2007). Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy. Molecular Medicine, 13(11-12), 584 - 591.

Cardoso, I., Almeida, M. R., Ferreira, N., Arsequell, G., et al. (2007). Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: Relevance in drug design. Biochemical Journal, 408(1), 131 - 138.

Altland, K., Benson, M. D., Costello, C. E., Ferlini, A., et al. (2007). Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis, 28(12), 2053 - 2064.

Santos, S. D., Cardoso, I., Magalhães, J., & Saraiva, M. J. (2007). Impairment of the ubiquitin-proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. Journal of Pathology, 213(2), 200 - 209.

Westermark, P., Benson, M. D., Buxbaum, J. N., Cohen, A. S., et al. (2007). A primer of amyloid nomenclature. Amyloid, 14(3), 179 - 183.

Gales, L., Saraiva, M. J., & Damas, A. M. (2007). Structural basis for the protective role of sulfite against transthyretin amyloid formation. Biochimica et Biophysica Acta - Proteins and Proteomics, 1774(1), 59 - 64.

Sousa, J. C., Cardoso, I., Marques, F., Saraiva, M. J., & Palha, J. A. (2007). Transthyretin and Alzheimer's disease: Where in the brain?. Neurobiology of Aging, 28(5), 713 - 718.

Fleming, C. E., Saraiva, M. J., & Sousa, M. M. (2007). Transthyretin enhances nerve regeneration. Journal of Neurochemistry, 103(2), 831 - 839.

Ruano, D., Macedo, A., Soares, M. J., Valente, J., et al. (2007). Transthyretin: No association between serum levels or gene variants and schizophrenia. Journal of Psychiatric Research, 41(8), 667 - 672.

Monteiro, F. A., Sousa, M. M., Cardoso, I., Do Amaral, J. B., et al. (2006). Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. Journal of Neurochemistry, 97(1), 151 - 161.

Morais-De-Sá, E., Neto-Silva, R. M., Pereira, P. J. B., Saraiva, M. J., & Damas, A. M. (2006). The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallographica Section D: Biological Crystallography, 62(5), 512 - 519.

Cardoso, I., & Saraiva, M. J. (2006). Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model. FASEB Journal, 20(2), 234 - 239.

Teixeira, P. F., Cerca, F., Santos, S. D., & Saraiva, M. J. (2006). Endoplasmic reticulum stress associated with extracellular aggregates: Evidence from transthyretin deposition in familial amyloid polyneuropathy. Journal of Biological Chemistry, 281(31), 21998 - 22003.

Terazaki, H., Ando, Y., Fernandes, R., Yamamura, K. - I., et al. (2006). Immunization in familial amyloidotic polyneuropathy: Counteracting deposition by immunization with a Y78F TTR mutant. Laboratory Investigation, 86(1), 23 - 31.

Monteiro, F. A., Cardoso, I., Sousa, M. M., & Saraiva, M. J. (2006). In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Letters, 580(14), 3451 - 3456.

Nunes, A. F., Saraiva, M. J., & Sousa, M. M. (2006). Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB Journal, 20(1), 166 - 168.

Westermark, P., Benson, M. D., Buxbaum, J. N., Cohen, A. S., et al. (2005). Amyloid: Toward terminology clarification: Report from the Nomenclature Committee of the International Society Of Amyloidosis. Amyloid, 12(1), 1 - 4.

Maia, F., Almeida, M. D. R., Gales, L., Kijjoa, A., et al. (2005). The binding of xanthone derivatives to transthyretin. Biochemical Pharmacology, 70(12), 1861 - 1869.

Gales, L., Macedo-Ribeiro, S., Arsequell, G., Valencia, G., et al. (2005). Human transthyretin in complex with iododiflunisal: Structural features associated with a potent amyloid inhibitor. Biochemical Journal, 388(2), 615 - 621.

Almeida, M. R., Gales, L., Damas, A. M., Cardoso, I., & Saraiva, M. J. (2005). Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Current Drug Targets: CNS and Neurological Disorders, 4(5), 587 - 596.

Soares, M. L., Coelho, T., Sousa, A., Batalov, S., et al. (2005). Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: Complexity in a single-gene disease. Human Molecular Genetics, 14(4), 543 - 553.

Sousa, J. C., Morreale de Escobar, G., Oliveira, P., Saraiva, M. J., & Palha, J. A. (2005). Transthyretin is not necessary for thyroid hormone metabolism in conditions of increased hormone demand. Journal of Endocrinology, 187(2), 257 - 266.

Sousa, M. M., Do Amaral, J. B., Guimarães, A., & Saraiva, M. J. (2005). Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB Journal, 19(1), 124 - 126.

Neto-Silva, R. M., Macedo-Ribeiro, S., Pereira, P. J. B., Coll, M., et al. (2005). X-ray crystallographic studies of two transthyretin variants: Further insights into amyloidogenesis. Acta Crystallographica Section D: Biological Crystallography, 61(3), 333 - 339.

Ohmori, H., Ando, Y., Makita, Y., Onouchi, Y., et al. (2004). Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy. Journal of medical genetics, 41(4).

Morais-De-Sá, E., Pereira, P. J. B., Saraiva, M. J., & Damas, A. M. (2004). The crystal structure of transthyretin in complex with diethylstilbestrol: A promising template for the design of amyloid inhibitors. Journal of Biological Chemistry, 279(51), 53483 - 53490.

Sousa, M. M., Ferraõ, J., Fernandes, R., Guimarães, A., et al. (2004). Deposition and passage of transthyretin through blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Laboratory Investigation, 84(7), 865 - 873.

Santos, S. D., & Saraiva, M. J. (2004). Enlarged ventricles, astrogliosis and neurodegeneration in heat shock factor 1 null mouse brain. Neuroscience, 126(3), 657 - 663.

Saraiva, M. J., Sousa, M. M., Cardoso, I., & Fernandes, R. (2004). Familial amyloidotic polyneuropathy: Protein aggregation in the peripheral nervous system. Journal of Molecular Neuroscience, 23(1-2), 35 - 40.

Soares, M. L., Coelho, T., Sousa, A., Holmgren, G., et al. (2004). Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: Genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden. European Journal of Human Genetics, 12(3), 225 - 237.

De Carvalho, M., Linke, R. P., Domingos, F., Evangelista, T., et al. (2004). Mutant fibrinogen A-?-chain associated with hereditary renal amyloidosis and peripheral neuropathy. Amyloid, 11(3), 200 - 207.

Almeida, M. R., Macedo, B., Cardoso, I., Alves, I., et al. (2004). Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 381(2), 351 - 356.

Liz, M. A., Faro, C. J., Saraiva, M. J., & Sousa, M. M. (2004). Transthyretin, a new cryptic protease. Journal of Biological Chemistry, 279(20), 21431 - 21438.